Avzo-023
HR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
116 Active assets in the HR+/HER2- Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
EXEMESTANE Fujian Cancer Hospital | Phase 4 | BBB |
Everolimus Ellipses Pharma | Phase 4 | BBB |
Arimidex University of Illinois at Chicago | Phase 4 | BBB |
Palbociclib BeOne Medicines | Phase 3 | BBB |
Ribociclib BeOne Medicines | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Avzo-023 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →